In conclusion, our review of a large multi-institutional US database of electronic health record data demonstrated that GLP-1 receptor agonist use was associated with a significant decrease in risk for multiple myeloma, but not acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndrome in patients with type 2 diabetes mellitus. The gene discussed is GLP1R; the disease is plasma cell myeloma.